Baird lowered the firm’s price target on Beta Bionics (BBNX) to $15 from $20 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which showed a solid start to the year but where compatitive uncertainties keep them on the sidelines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Positive Developments and Strong Financial Performance Drive Buy Rating for Beta Bionics, Inc.
- Beta Bionics Reports Strong Q1 2025 Results and Raises Guidance
- Beta Bionics reports Q1 EPS (93c), consensus (51c)
- Beta Bionics raises FY25 revenue view to $82M-$87M from $80M-$85M
- BBNX Earnings Report this Week: Is It a Buy, Ahead of Earnings?